ULCERATIVE COLITIS

This study tested an experimental drug called ABBV-668 in 30 adults with moderate to severe ulcerative colitis, a condition causing inflammation and bleeding in the colon. Participants took the drug as capsules twice daily for 16 weeks, with a 30-day follow-up. The goal was to se…

This study tested a new daily medication called ABX464 in 639 adults and teens with moderate-to-severe ulcerative colitis who had not responded well to other treatments. The goal was to see if ABX464 could help bring about remission (symptom relief and healing of the colon) after…

This study looked at how safe and effective the drug upadacitinib (RINVOQ) is for Korean adults with moderate to severe ulcerative colitis or Crohn's disease. About 600 participants took the drug as prescribed by their doctor and were followed for up to 52 weeks. The main goal wa…

This study looked at whether a tailored physical activity program could help improve bone density in children and teens with inflammatory bowel disease (IBD). Fifteen participants completed the program. The goal was to see if exercise could counteract bone loss caused by the dise…

This study looked at the long-term safety and effectiveness of the drug vedolizumab (Entyvio) in over 1,100 people with moderate to severe ulcerative colitis. Participants had not responded well to other treatments. The goal was to see how well the drug works and what side effect…

This study looked at whether switching from a low-concentration to a high-concentration adalimumab injection (AVT-02) causes less pain at the injection site. It included 324 adults with conditions like Crohn's disease, rheumatoid arthritis, and psoriasis. Researchers measured pai…

This study looked at whether eating gluten-free can reduce stomach symptoms and tiredness in people with ulcerative colitis. Fifteen adults each spent one week on a gluten-free diet plus a special granola bar, and another week on the same diet but with a high-gluten bar. They rep…

This study looked at whether a short-term, plant-based low-calorie diet (called a fasting mimicking diet) could improve depressive symptoms in people with inflammatory bowel disease (IBD). 42 adults with IBD and mild-to-moderate depression completed three 5-day diet cycles. Resea…

This study looked at whether simple, low-cost blood tests can help track how active ulcerative colitis is. Researchers measured different ratios of blood cells and proteins in 80 patients and compared them to standard colonoscopy and stool tests. The goal was to see if these bloo…

This early-stage study tested whether the oral drug MB-001 is safe in 48 healthy adults aged 18 to 65. Participants received either a single dose or five daily doses of the drug or a placebo, and stayed in the clinic for five days after the last dose. The main goal was to check f…

This study looked at whether regularly measuring levels of anti-TNF drugs and antibodies in the blood helps doctors make better treatment decisions for people with Crohn's disease or ulcerative colitis. 260 patients were split into two groups: one where doctors used these test re…

This study looked back at 50 adults with Crohn's disease who were treated with two newer biologic drugs, Ustekinumab and Vedolizumab. The goal was to see how well the drugs controlled the disease and what side effects occurred. Researchers also wanted to find out which patient fa…

This study looked at 211 adults with long-standing inflammatory bowel disease (IBD) to see which colonoscopy method finds precancerous growths better: high-definition white light or dye spraying. Both are standard techniques used during screening. The goal was to learn which appr…

This study watched 165 people with inflammatory bowel disease (Crohn's or colitis) in Poland as they started or continued vedolizumab treatment. Researchers did not give any treatment – they simply recorded whether patients chose intravenous (IV) or at-home injections, and tracke…

This study examined infection rates in nearly 24,000 older adults (65+) with ulcerative colitis or Crohn's disease who started treatment with ENTYVIO, TNF-alpha inhibitors, or ustekinumab. Using Medicare claims data from 2016 to 2025, researchers compared how many people had seri…